Table 1.

The concentrations of urinary miRNAs in patients with FSGS and controls in the validation cohort

microRNAsConcentration of Urinary miRNAs (fmol/L)Fold Change for FSGS-A versus Controls Fold Change for FSGS-A versus FSGS-CR
ControlsFSGS-CRFSGS-AP ValueMeanP ValueMeanP Value
Confirmation set
 hsa-miR-135b46.5±45.148.8±28.4106±85.60.012.300.0042.220.01
 hsa-miR-1552590±19706990±575013,300±11,1000.0015.14<0.0011.910.04
 hsa-miR-196a208±99.3190±80.61350±10400.016.510.0047.110.01
 hsa-miR-30a-5p281±196397±164855±6730.0013.05<0.0012.150.01
 hsa-miR-320238±123763±6151590±1060<0.0016.70<0.0012.090.004
 hsa-miR-49033.1±28.327.5±12.5107±96.00.033.240.033.890.03
Validation set
 hsa-miR-135b105±159117±152140±1650.700.430.58
 hsa-miR-1552380±20804920±477012,300±10,900<0.0013.33<0.0012.49<0.001
 hsa-miR-196a165±140205±1951250±1090<0.0016.74<0.0016.08<0.001
 hsa-miR-30a-5p489±326390±3281230±1110<0.0012.81<0.0013.15<0.001
 hsa-miR-3201980±18901960±19502060±22800.270.110.17
 hsa-miR-49042.9±33.069.3±56.0262±219<0.0014.68<0.0013.80<0.001
  • Data are expressed as the mean±SD unless otherwise indicated. P values were calculated by one-way ANOVA analysis followed by Student–Newman–Keuls analysis. miRNAs, microRNAs; FSGS-CR, FSGS in remission; FSGS-A, active FSGS.